Long-term ultra-low-dose aspirin therapy and platelet function

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Hematology

Background:

• Aspirin is widely used for its antiplatelet effects.
• Understanding the efficacy of ultra-low doses is crucial for optimizing therapeutic strategies.
• Platelet aggregation and thromboxane B2 (TXB2) production are key markers of aspirin's action.

Purpose of the Study:

• To compare the effects of two ultra-low aspirin doses (162 mg/d and 20 mg/d) on platelet function.
• To determine the duration of antiplatelet effect for a 20 mg/d aspirin dose.
• To assess the threshold dose for maintaining adequate platelet inhibition.

Main Methods:

• Two groups of healthy subjects received either 162 mg/d or 20 mg/d of aspirin for 4 weeks.
• Platelet aggregation and thromboxane B2 (TXB2) production were measured throughout the study period.
• Dose escalation to 40 mg/d was performed for subjects showing diminished response.

Main Results:

• Both aspirin doses initially inhibited platelet aggregation and TXB2 production similarly.
• After 4 weeks, significantly less platelet aggregation inhibition was observed in the 20 mg/d group.
• Two subjects on 20 mg/d showed 'escape' from aspirin's effect, responding to 40 mg/d.

Conclusions:

• A daily aspirin dose of 20 mg is insufficient to maintain adequate platelet function inhibition in normal subjects over time.
• Higher doses may be required for sustained antiplatelet therapy, even at the lower end of the therapeutic range.
• Individual variability in response to low-dose aspirin necessitates careful consideration of dosage and monitoring.